Why I Wouldn't Touch Novavax With a 10-Foot Pole
(NASDAQ: NVAX) was once a leading contender to dominate the coronavirus vaccine market. The company faced several challenges, however, and although it successfully launched its vaccine, Nuvaxovid, revenue and earnings have remained inconsistent for years, and the stock has delivered subpar returns. Unfortunately for Novavax, it is unlikely to perform significantly better over the medium term.
Here's why it'd be best for investors to avoid this company.
Image source: Getty Images.
Source Fool.com
Novavax Inc. Aktie
7,25 €
2,11 %
Novavax Inc. wird von der Community leicht favorisiert: Mehr Buy- als Sell-Einschätzungen.
Ein Kursziel von 8 € für Novavax Inc. impliziert ein leicht positives Wachstum gegenüber dem aktuellen Kurs von 7.25 €.
